Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

962 - A novel Tc-99m and fluorescence labeled peptide: Multimodal imaging agent for targeting angiogenesis in a murine tumor model


10 Oct 2016


Poster display


Dae-Weung Kim


Annals of Oncology (2016) 27 (6): 401-406. 10.1093/annonc/mdw380


D. Kim1, S. Kim2, M.H. Kim3, W.H. Kim4, C.G. Kim3

Author affiliations

  • 1 Department Of Nuclear Medicine And Research Unit Of Molecular Imaging Agent (rumia), Wonkwang University Hospital, 570-711 - Iksan/KR
  • 2 Research Unit Of Molecular Imaging Agent (rumia), Wonkwang University Hospital, Iksan/KR
  • 3 Department Of Nuclear Medicine, Wonkwang University Hospital, Iksan/KR
  • 4 Department Of Nuclear Medicine, Chonbuk National University Medical School and Hospital, Jeon Ju/KR


Abstract 962


The serine-aspartic acid-valine (SDV) peptide binds specifically to integrin αvß3. In the present study, we successfully developed both Tc-99m and TAMRA labeled TAMRA-GHEG-ECG-SDV peptide to target the integrin αvß3 of tumor cells; furthermore, we evaluated the diagnostic performance of Tc-99m TAMRA-GHEG-ECG-SDV as a dual-modality imaging agent for tumor of the murine model.


TAMRA-GHEG-ECG-SDV synthesized using Fmoc solid-phase peptide synthesis. Radiolabeling of TAMRA-GHEG-ECG-SDV with Tc-99m was done using ligand exchange methods. Labeling stability and cytotoxicity studies were performed. Gamma camera imaging, biodistribution and ex vivo imaging studies were performed in murine models with HT-1080 and HT-29 tumors. Tumor tissue slide was prepared and analyzed using confocal microscopy.


After radiolabeling procedures with Tc-99m, the Tc-99m TAMRA-GHEG-ECG-SDV complexes were prepared in high yield (>99%). Tc-99m TAMRA-GHEG-ECG-SDV was found to be nontoxic to HUVEC and HT-1080 cells at all concentration. On gamma camera imaging study, a substantial uptake of Tc-99m TAMRA-GHEG-ECG-SDV into HT-1080 tumor (integrin αvß3-positive) and low uptake of Tc-99m TAMRA-GHEG-ECG-SDV in HT-29 tumor (integrin αvß3-negative) were demonstrated. The HT-1080 tumor-to-normal muscle uptake ratio of Tc-99m TAMRA-GHEG-ECG-SDV reached 6.8 ± 2.3 at 3 h (2.8 ± 0.7, 5.3 ± 1.5 and 6.8 ± 2.3 at 1, 2 and 3 h, respectively). The HT-29 tumor-to-normal muscle uptake ratios of Tc-99m TAMRA-GHEG-ECG-SDV (1.6 ± 0.4, 1.7 ± 0.4 and 2.0 ± 0.5 at 1, 2 and 3 h, respectively) were significantly lower than those of HT-1080 tumor (p 


Our in vivo and in vitro studies revealed substantial uptake of Tc-99m TAMRA-GHEG-ECG-SDV on the integrin αvß3-positive tumor. Tc-99m TAMRA-GHEG-ECG-SDV could be a good candidate for dual-modality imaging agent targeting tumor angiogenesis.

Clinical trial identification


Legal entity responsible for the study

Wonkwang University School of Medicine


This work was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education (2013R1A1A2059262).


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings